Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2015 by Mayo Clinic
National Cancer Institute (NCI)
FDA Office of Orphan Products Development
Information provided by (Responsible Party):
Mayo Clinic
ClinicalTrials.gov Identifier:
First received: October 28, 2009
Last updated: September 29, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)